ABC Arbitrage SA Purchases New Stake in Genmab A/S Sponsored ADR $GMAB

ABC Arbitrage SA purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 105,871 shares of the company’s stock, valued at approximately $3,261,000.

Several other institutional investors have also recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its stake in shares of Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after buying an additional 1,174 shares in the last quarter. Sei Investments Co. boosted its stake in Genmab A/S by 4.2% during the 2nd quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after purchasing an additional 2,496 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after purchasing an additional 81,434 shares in the last quarter. Quantinno Capital Management LP increased its holdings in Genmab A/S by 64.9% during the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock worth $3,267,000 after purchasing an additional 62,226 shares in the last quarter. Finally, Raymond James Financial Inc. raised its stake in shares of Genmab A/S by 48.1% in the second quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock worth $643,000 after purchasing an additional 10,113 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $26.18 on Tuesday. The company has a market capitalization of $16.32 billion, a P/E ratio of 19.83, a P/E/G ratio of 1.17 and a beta of 0.86. The business has a fifty day simple moving average of $27.20 and a two-hundred day simple moving average of $29.86. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. Genmab A/S Sponsored ADR has a 1 year low of $18.89 and a 1 year high of $35.43.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a net margin of 21.05% and a return on equity of 15.34%. On average, analysts expect that Genmab A/S Sponsored ADR will post 1.19 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on GMAB shares. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Wells Fargo & Company began coverage on Genmab A/S in a research report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price target for the company. Guggenheim dropped their price objective on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Truist Financial raised shares of Genmab A/S to a “strong-buy” rating in a report on Monday, April 27th. Finally, The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $39.07.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.